Low molecular weight heparin for the out-of-hospital treatment of venous thrombosis: Rationale and clinical results

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 689-692

  Hirsh, Jack ^a   Crowther, Mark ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; HEPARIN; HEPARIN BINDING PROTEIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; HOME CARE; HUMAN; MACROPHAGE; ORAL DRUG ADMINISTRATION; OSTEOPENIA; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

EID: 0030811933     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657613     Document Type: Conference Paper

References (33)

1. Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, McLoughlin D, Armstrong P. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. New Engl J Med 1979; 301: 855-8.
2. Hirsh J. The optimal duration of anticoagulant therapy for venous thrombosis. New Engl J Med 1995; 332: 1710-1.
3. Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, Hirsh J, Martin GJ, Green D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. New Engl J Med 1990; 322: 1260-4.
4. Hirsh J. Heparin. New Engl J Med 1991; 324: 1565-74.
5. Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WHR, Rosenbloom D, Sackett DL, Anderson C, Harrison L, Gent M. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. New Engl J Med 1986; 315: 1109-14.
6. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey HI. Oral anticoagulants; Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995; 108(4): 231s-46s.
7. Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, Turpie AGG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockelford P. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. New Engl J Med 1982; 307: 1676-81.
8. Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med 1989; 87: 153-9.
9. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-52.
10. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, Van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, Bossuyt PMM, DeHaes H, Van Den Belt AGM, Sagnard L, D'Azemar P, Buller HR, for the TASMAN study group. Treatment of patients with proximal-vein thrombosis with intravenous unfractionated heparin in hospital compared with subcutaneous low-molecular-weight heparin out of hospital or with early discharge. New Engl J Med 1996; 334: 682-7.
11. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg JS, Turpie AG, Demers C, Kovacs M, Geerts W, Kassis J, Desjardins L, Cusson J, Cruickshank M, Powers P, Brien W, Haley S, Willan A. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New Engl J Med 1996; 334: 677-81.
12. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 7-11.
13. Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla F, Poli TT, Tagliaferri A, Dettori AG. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994; 72: 191-7.
14. Kakkar VV. Dalteparin prevention of recurrent DVT-a study versus warfarin. Haemostasis 1994; 24(Suppl. 1): s45
15. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
16. Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharm 1988; 28: 609-18.
17. Briant L, Caranobe C, Saivin S, Sie P, Bayrou B, Houin G, Boneu B. Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit. Thromb Haemost 1989; 61: 348-53.
18. Bratt G, Tornebohm E, Widlund L, Lockner D. Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986; 42: 613-20.
19. Matzsch T, Bergqvist D, Hedner U, Ostergaard P. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987; 57: 97-101.
20. Handeland GF, Abildgaard U, Holm HA, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharm 1990; 39: 107-12.
21. Boneu B, Buchanan MR, Caranobe C, Gabaig AM, Dupouy D, Sie P, Hirsh J. The disappearance of a low molecular weight heparin fraction (CY 216) differs from standard heparin in rabbits. Thromb Res 1987; 46: 845-53.
22. Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994; 71: 300-4.
23. Young E, Cosmi B, Weitz J, Hirsh J. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. Thromb and Haemost 1993; 70: 625-30.
24. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent MK, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. New Engl J Med 1995; 332: 1330-5.
25. Murray WJ, Lindo VS, Kakkar VV, Melissari E. Long-term administration of heparin and heparin fractions and osteoporosis in experimental animals. Blood Coag Fibrin 1995; 6: 113-8.
26. Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-45.
27. Esquivel CO, Bergqvist D, Bjorck CG, Nilsson B. Comparison between commercial heparin, low molecular weight heparin and pentosan polysulfate on hemostasis and platelets in vivo. Thromb Res 1982; 28: 389-99.
28. Cade JF, Buchanan MR, Boneu B, Ockelford P, Cater CJ, Cerskus ALH, Hirsh J. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 1984; 35: 613-25.
29. Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 1982; 25: 475-85.
30. Andriuoli G, Mastacchi R, Barbanti M, Sarret M. Comparison of the antithrombotic and haemorrhagic effects of heparin and a new low molecular weight heparin in rats. Haemostasis 1985; 15: 324-30.
31. Bergqvist D, Nilsson B, Hedner U, Pedersen PC, Ostergaard PB. The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis. Thromb Res 1985; 38: 589-601.
32. Lindmarker P, Holmstrom M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis is. A feasibility and health economic study in an outpatient setting. J Int Med 1996;240:395-401
33. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Int Med 1995; 155: 601-7.